Cargando…

An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques

The immunogenicity and protective efficacy of a candidate tetravalent dengue virus purified inactivated vaccine (TDENV PIV) formulated with alum or an Adjuvant System (AS01, AS03 tested at three different dose levels, or AS04) was evaluated in a 0, 1-month vaccination schedule in rhesus macaques. On...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandez, Stefan, Thomas, Stephen J., De La Barrera, Rafael, Im-erbsin, Rawiwan, Jarman, Richard G., Baras, Benoît, Toussaint, Jean-François, Mossman, Sally, Innis, Bruce L., Schmidt, Alexander, Malice, Marie-Pierre, Festraets, Pascale, Warter, Lucile, Putnak, J. Robert, Eckels, Kenneth H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385761/ https://www.ncbi.nlm.nih.gov/pubmed/25646261 http://dx.doi.org/10.4269/ajtmh.14-0268

Ejemplares similares

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States
por: Schmidt, Alexander C., et al.
Publicado: (2017)

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico
por: Diaz, Clemente, et al.
Publicado: (2018)

Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2020)

Characterization of recent and minimally passaged Brazilian dengue viruses inducing robust infection in rhesus macaques
por: Borges, Maria Beatriz, et al.
Publicado: (2018)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1
por: Friberg, Heather, et al.
Publicado: (2020)

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice
por: Larocca, Rafael A., et al.
Publicado: (2021)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
por: Moris, Philippe, et al.
Publicado: (2019)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
por: Friberg, Heather, et al.
Publicado: (2022)

Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines
por: Borges, Maria Beatriz, et al.
Publicado: (2019)

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial
por: Martinez, Luis Javier, et al.
Publicado: (2015)

Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques
por: McCracken, Michael K., et al.
Publicado: (2021)

A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults
por: Thomas, Stephen J., et al.
Publicado: (2013)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine
por: Simmons, Monika, et al.
Publicado: (2016)

Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study
por: Diaz, Clemente, et al.
Publicado: (2020)

Virological and Immunological Outcomes in Rhesus Monkeys after Exposure to Dengue Virus–Infected Aedes aegypti Mosquitoes
por: Carrington, Lauren B., et al.
Publicado: (2020)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

RNA Editome in Rhesus Macaque Shaped by Purifying Selection
por: Chen, Jia-Yu, et al.
Publicado: (2014)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus
por: Pantoja, Petraleigh, et al.
Publicado: (2017)

Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes
por: Li, Leike, et al.
Publicado: (2019)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
por: Lin, Leyi, et al.
Publicado: (2020)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques
por: George, Jeffy, et al.
Publicado: (2017)

Dengue Virus Exposures Among Deployed U.S. Military Personnel
por: Hesse, Elisabeth M., et al.
Publicado: (2017)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
por: El Fezzazi, Hanna, et al.
Publicado: (2017)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever
por: Subramaniyan, Vijayakumar, et al.
Publicado: (2018)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gdtr9kgmkoub87goa7d3k0l0c4